Biktarvy Price in India 2026: $91/month Generic — Is It Safe?

One of the most striking facts in global medicine is that the very same HIV drug can cost wildly different amounts depending on which country you are standing in. Brand-name Biktarvy carries a US list price of roughly $140 per tablet. In India, the licensed generic of the same three-drug combination sells for a small fraction of that. This page explains, transparently and per tablet, why that gap exists — what the drug actually costs in India, who makes it and under what licences, and what the US price looks like by comparison.

This is a price-transparency explainer, not a buying guide. SunnyPharma is an education resource: we do not sell medication, take orders, or direct anyone to a supplier. The goal here is simply to make a confusing global pricing picture legible.

This is a cluster page within our HIV Medications topic guide. For the full Biktarvy overview, see the Biktarvy Generic pillar page.

The Price Gap at a Glance — 2026

What Biktarvy Costs in India, Per Tablet

There is no single “India price.” What the licensed generic costs depends heavily on where and how it is bought, so the honest way to read these figures is as approximate ranges that move from week to week.

At a domestic Indian pharmacy, the licensed generic (Taffic by Hetero Labs) commonly sells for around ₹4,000 for a 30-tablet bottle — roughly $47 at current exchange rates, or about $1.55 per tablet. This is the in-country retail price paid by residents.

Through international channels, the same product typically appears in the range of $90–$150 for a 30-tablet bottle — about $3–$5 per tablet. The difference reflects international shipping, currency conversion, handling, and compliance costs layered on top of the domestic price.

Active Ingredients — Identical to Brand-Name Biktarvy

The Licensed Generic: Who Makes It, Under What Authority

The generic version of Biktarvy most widely produced in India is Taffic™, manufactured by Hetero Labs — one of India’s largest pharmaceutical companies and among the world’s largest producers of antiretroviral drugs. It is not a counterfeit. It is a legitimately licensed generic produced under explicit authorization from Gilead Sciences, the originator of Biktarvy.

The legitimacy rests on a specific chain of licences and certifications:

• Voluntary licence from Gilead Sciences, granted through the Medicines Patent Pool (MPP) — a United Nations-backed public-health body. This licence removes the patent barrier for designated countries and authorizes named manufacturers to produce the drug in exchange for a royalty to Gilead.
• DCGI / CDSCO approval — Taffic is approved by India’s Central Drugs Standard Control Organisation, the national drug regulator, India’s equivalent of the FDA.
• US FDA cGMP-certified facility — Hetero’s relevant manufacturing sites in Hyderabad are certified to US current Good Manufacturing Practice standards and are subject to FDA inspection.
• Global procurement track record — Hetero has supplied antiretrovirals to PEPFAR and WHO procurement programs for over two decades.

Why the Price Is So Much Lower

1. Voluntary licensing removes the patent barrier

Gilead granted voluntary licences to manufacturers like Hetero through the Medicines Patent Pool. These licences permit generic production in designated, mostly lower- and middle-income countries. The manufacturer pays Gilead a royalty and prices the drug at manufacturing cost plus margin — not at patent-protected brand pricing.

2. India’s manufacturing cost structure

India is the world’s largest exporter of generic medicines. Decades of manufacturing infrastructure, a deep domestic active-ingredient supply chain, and lower input costs produce genuinely lower per-unit costs — without lower quality standards, as the cGMP certification shows.

3. No US-market cost overhead

The US list price reflects FDA approval and regulatory costs, US marketing and sales infrastructure, pharmacy benefit manager rebate negotiations, and litigation reserves. A generic produced under an MPP voluntary licence carries none of these.

US prescription drug prices are, on average, several times higher than in other countries. For medicines that have licensed generic equivalents available abroad but not in the US, the gap is at its most extreme.
— RAND Corporation, International Prescription Drug Price Comparisons

What Biktarvy Costs in the US, Per Tablet

For comparison, here is the other end of the gap. Brand-name Biktarvy in the United States carries a list price — the wholesale acquisition cost (WAC) — of $4,216 for a 30-tablet bottle, which is approximately $140.53 per tablet, per Gilead’s published 2026 pricing.

A Note on Importation

Because this page is about prices in different countries, it is worth stating the legal reality plainly. Under US federal law, importing non-FDA-approved drugs is generally illegal. The FDA has at times exercised enforcement discretion in narrow personal-use situations, but enforcement discretion is not the same as a legal right, and it can change at any time. This page does not advise anyone to import medication, and nothing here should be read as encouragement to do so.

People access medicines under very different rules depending on where they live, and laws differ by country. Anyone weighing where and how they obtain an HIV medication should do two things: understand the law that applies to them, and talk to their own clinician. Source: FDA Personal Importation policy.

Frequently Asked Questions